Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report
Yuanxiang Li,* Yang Hu,* Bin Yang, Caibao Jin, Hui Ren, Jingyi Wu, Zhijun Wang, Youying Wei, Ling Yang, Yanping Hu Department of Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People’s Republic of China&am...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bad2ceccf85643c5801d75cad0079802 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Yuanxiang Li,* Yang Hu,* Bin Yang, Caibao Jin, Hui Ren, Jingyi Wu, Zhijun Wang, Youying Wei, Ling Yang, Yanping Hu Department of Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yanping HuDepartment of Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People’s Republic of ChinaEmail h-y-p@126.comAbstract: PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is relatively rare but may become fatal. We will present a case of a male patient who experienced immunotherapy-related cardiotoxicity one year after received pembrolizumab treatment. The patient had atypical symptom presentation initially, but his condition deteriorated worsened rapidly and he developed severe cardiac disease. The patient experienced significant relief after corticosteroid treatment. Unfortunately, he experienced a reoccurence of the severe adverse event when discontinuing the use of corticosteroids. Ultimately, larger doses and longer courses of corticosteroid treatment cured the heart damage. Fortunately, we observed that lesions were stable and maintained for a long time after cessation of using pembrolizumab for eight months.Keywords: PD-1/PD-L1 inhibitors, immune-related cardiotoxicity, non-small cell lung cancer |
|---|